Informations

With the release of data from studies such as DESTINY-Breast09 (DB-09), antibody–drug conjugates (ADCs) are gaining increasing prominence in the first-line treatment of HER2-positive metastatic breast cancer (MBC). However, while the traditional THP regimen (trastuzumab + pertuzumab + taxane) remains firmly established as the guideline-preferred standard, the question remains: has the “era of ADC dominance”…

In the era of neoadjuvant immunotherapy for triple-negative breast cancer (TNBC), an important clinical question has emerged: is platinum still indispensable? During the “Deep Dive” session at the 8th North–South Breast Cancer Forum, Professor Jia Wang from Zhongshan Hospital, Dalian University presented an in-depth analysis of this issue. Drawing on treatment goals, mechanistic rationale, clinical…

On March 16, 2026, the long-term follow-up results of the randomized, double-blind, multicenter Phase III PHILA study were published online in The BMJ. The corresponding author is Academician Binghe Xu from the Cancer Hospital, Chinese Academy of Medical Sciences, with Professor Fei Ma (Cancer Hospital, Chinese Academy of Medical Sciences) and Professor Min Yan (Henan…

Precision testing is only as valuable as its timing. During the “Deep Dive” session at the 8th North–South Breast Cancer Forum, Professor Hao Wang from Sichuan Cancer Hospital delivered a focused presentation on the optimal timing of endocrine-related molecular testing in patients with HR+/HER2– metastatic breast cancer.

On March 14, 2026, the international oncology journal Annals of Oncology (2025 IF: 65.4), the official journal of the European Society for Medical Oncology (ESMO), published the results of the international multicenter phase III OPTIMAL trial (NCT03315364). The study was led by Academician Binghe Xu (first author) from the National Cancer Center/Cancer Hospital, Chinese Academy…

Antibody–drug conjugates (ADCs) are reshaping the treatment landscape of breast cancer at an unprecedented pace. From HER2 to Trop-2, and from late-line metastatic settings to early-stage neoadjuvant therapy, ADC indications continue to expand while efficacy breakthroughs accumulate. Oncology Frontier invited Professor Jian Zhang from Fudan University Shanghai Cancer Center and Professor Songqing Ye from Fujian…

With the arrival of spring, the 8th Tongji Breast Cancer Forum was successfully convened, focusing on key topics including clinical needs, cutting-edge advances, grassroots implementation, and the development of young physicians. The meeting not only built a bridge for in-depth dialogue between leading experts and frontline clinicians, but also offered fresh perspectives on integrating clinical…

From April 10 to 12, 2026, the National Breast Cancer Conference will be held in Beijing. Marking the 10th anniversary of the Breast Cancer Committee of the Chinese Society of Clinical Oncology (CSCO BC), this annual flagship meeting will once again bring together leading experts from China and around the world to share cutting-edge research,…